Drugs / biphasic insulin aspart 50
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01242826 | Feb → Mar 2011 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01536028 | Apr → Jul 2006 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01520831 | Apr 1999 → May 2000 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00627445 | Feb 2008 → Jan 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01892020 | Jun 2013 → May 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | biphasic insulin aspart 50 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01892020 ↗ |
| Known as | BIAsp 50 | “after a single subcutaneous (under the skin) injection of biphasic insulin aspart 50 (BIAsp 50).” NCT01242826 ↗1“The new formulations BIAsp 50 and BIAsp 70 contain 50% and 70% soluble IAsp, respectively.” PMID 19049377 ↗ Dec 2008 |
| Route | Subcutaneous | “s.c. (under the skin) injection before breakfast and lunch” NCT00627445 ↗ |